Pfizer's next-gen pneumonia shot beats Prevnar 20 in infant trial

Pfizer has reported positive Phase 2 trial data showing its next-generation 25-valent pneumococcal vaccine candidate (25vPnC, PF-07872412) elicits significantly stronger immune responses than Prevnar 20, especially against the key serotype 3 strain, and is expected to cover up to 90% of disease-causing serotypes in young children. The trial compared 25vPnC against Prevnar 20 in a four‑dose infant schedule and found serotype‑3 antibody levels about 9–15‑fold higher with Pfizer’s 25v candidate after doses 3 and 4, positioning it as a potential successor to Prevnar 20 in pediatric pneumonia prevention.